Exact Sciences - 53 Year Dividend History | EXAS
Historical dividend payout and yield for Exact Sciences (EXAS) since 1971. The current TTM dividend payout for Exact Sciences (EXAS) as of November 19, 2024 is $0.00. The current dividend yield for Exact Sciences as of November 19, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$9.979B |
$2.500B |
|
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
